- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Pembrolizumab (urothelial cancer) – July 2018
Pembrolizumab (urothelial cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
26 October 2018